Servier

Digital

pharmaphorum podcast Episode 242, Yann Gaston-Mathe, Iktos

JPM2026: Broadening AI drug discovery to include the lab, wi...

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

News

Iktos' Chemspeed robotics-powered chemistry platform

Servier signs €1bn-plus AI pact with Iktos

In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

News

Insilico Medicine and Servier logos on a black background

Insilico adds Servier to partnership roster with $888m deal

Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.

News

Servier bets $450m on Fragile X syndrome drug

Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

Oncology

Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat...

At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.

JPM2026: Broadening AI drug discovery to include the lab, wi...

Now Iktos teams up with Pierre Fabre in oncology

Servier signs €1bn-plus AI pact with Iktos

Insilico adds Servier to partnership roster with $888m deal

Servier bets $450m on Fragile X syndrome drug

Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat...

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Servier

Editor's Picks